Payment overview · 2025
General Payments
$452.75
31 reported records · 6 companies
Healthcare provider profile · identity verified
Kim Hestand, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ROSWELL, NM · NPI 1104356963
Verified facts
What the public records show
CMS Open Payments records show Kim Hestand, CNP received $452.75 in general payments during 2025 across 31 reported records.
AstraZeneca Pharmaceuticals LP accounted for 41.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Ubrelvy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $186.23 | 41.1% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $175.10 | 38.7% | 16 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.19 | 7.5% | 2 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$20.44 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.91 | 4.4% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.88 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $452.75 | 31 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $109.16 | 12 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $109.16 | 12 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $97.57 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $65.94 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.22 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $34.44 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $34.19 | 2 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 271 | 79 |
| Levothyroxine Sodium | Levothyroxine Sodium | 232 | 60 |
| Lisinopril | Lisinopril | 199 | 58 |
| Losartan Potassium | Losartan Potassium | 192 | 47 |
| Metformin Hcl | Metformin Hcl | 159 | 41 |
| Gabapentin | Gabapentin | 156 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 148 | 43 |
| Omeprazole | Omeprazole | 124 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 34 |
| Montelukast Sodium | Montelukast Sodium | 110 | 31 |
| Sertraline Hcl | Sertraline Hcl | 110 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 104 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 92 | 38 |
| Alendronate Sodium | Alendronate Sodium | 86 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 81 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 66 | 21 |
| Simvastatin | Simvastatin | 62 | 17 |
| Trazodone Hcl | Trazodone Hcl | 58 | 18 |
| Memantine Hcl | Memantine Hcl | 57 | 15 |
| Potassium Chloride | Potassium Chloride | 56 | 22 |
| Furosemide | Furosemide | 55 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 11 |
| Azithromycin | Azithromycin | 43 | 35 |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 30 |
| Ibuprofen | Ibuprofen | 41 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 13 |
| Ezetimibe | Ezetimibe | 39 | suppressed |
| Meloxicam | Meloxicam | 39 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | suppressed |
| Allopurinol | Allopurinol | 36 | 11 |
| Glipizide Er | Glipizide | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 31 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 29 | suppressed |
| Chlorthalidone | Chlorthalidone | 28 | suppressed |
| Estradiol | Estradiol | 28 | 12 |
| Glipizide | Glipizide | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Cefdinir | Cefdinir | 22 | 17 |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Alprazolam | Alprazolam | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Glimepiride | Glimepiride | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 16 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 16 | suppressed |
| Prednisone | Prednisone | 16 | 14 |
| Primidone | Primidone | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Lovastatin | Lovastatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $452.75 · 31 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, FARXIGA, QULIPTA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, VALTOCO, VRAYLAR, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ubrelvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error